Interesting ... I wonder if this "cost-effectiveness" will be replicated in the Mesoblast off the shelf CAR-T therapies partnered with Cartherics ?
https://www.globenewswire.com/news-...-based-Immunotherapies-for-Solid-Cancers.html
Study demonstrating the cost-effectiveness of #CART #celltherapy for r/r #mantlecell #lymphoma. #synthetic #biology #diagnostics #vaccines #celltherapy #cellulartherapeutics #celltherapyrx #crisprcas9 #crispr #immunotherapy #immunooncology
Cell Therapy News/Articles, page-8442
-
- There are more pages in this discussion • 9,804 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |